SCHEMBL933923

SCHEMBL933923

CC(C)(C)OC(=O)N1CCN(C(=O)OCc2ccccc2)[C@H](C(=O)O)C1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.55
PDK2 Q15119 1/20 0.55
PDK3 Q15120 1/20 0.55
PDK4 Q16654 1/20 0.55
PARP1 P09874 1/20 0.53
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PREP P48147 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375852 1.00 PDK1 (0.55) PDK1PDK2PDK3PDK4PARP1
SCHEMBL2442588 1.00 PDK1 (0.55) PDK1PDK2PDK3PDK4PARP1
SCHEMBL1375861 0.95 PARP1 (0.58) PDK1PDK2PDK3PDK4PARP1
SCHEMBL957813 0.95 PARP1 (0.58) PDK1PDK2PDK3PDK4PARP1
SCHEMBL3766378 0.95 PARP1 (0.58) PDK1PDK2PDK3PDK4PARP1
SCHEMBL7493594 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1
SCHEMBL30289331 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1
SCHEMBL7492256 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1
SCHEMBL3779343 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1
SCHEMBL30729617 0.92 PDK1 (0.54) PDK1PDK2PDK3PDK4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368625-A1 PIPERAZINES Grünenthal GmbH (DE) 2025-12-04 US disclosed
WO-2023178378-A1 MIP INHIBITORS DMTC Limited (AU) 2023-09-28 WO disclosed
EP-3233889-B1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
CN-107257803-B Polymyxin antibacterial agents for the treatment of bacterial infections 上海盟科药业股份有限公司 2021-02-05 CN disclosed
EP-3558980-B1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2021-01-27 EP disclosed
EP-3558980-B1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2021-01-27 EP disclosed
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-10-27 US disclosed
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-10-27 US disclosed
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-03-26 US disclosed
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) 2020-03-26 US disclosed
US-6911442-B1 Quinoline derivatives as antibacterials SMITHKLINE BEECHAM P.L.C. (GB) 2005-06-28 US disclosed
EP-1497273-A2 HYDROXAMIC ACID DERIVATIVES Novartis AG (CH) 2005-01-19 EP disclosed
US-6803369-B1 INHIBIT A BIOLOGICAL ACTIVITY OF A TOPOISOMERASE ENZYMES SMITHKLINE BEECHAM CORPORATION 2004-10-12 US disclosed
EP-1441729-A1 PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR SMITHKLINE BEECHAM PLC (GB) 2004-08-04 EP disclosed
EP-1187828-B1 QUINOLINE DERIVATIVES AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2004-04-21 EP disclosed
US-20030203917-A1 Compounds and methods for the treatment of neoplastic disease SMITHKLINE BEECHAM CORPORATION AND SMITHKLINE BEECHAM P.L.C. 2003-10-30 US disclosed
WO-2003084941-A2 HYDROXAMIC ACID DERIVATIVES NOVARTIS AG (CH) 2003-10-16 WO disclosed
WO-2003041711-A1 PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR SMITHKLINE BEECHAM P.L.C. (GB) 2003-05-22 WO disclosed
EP-1187828-A1 QUINOLINE DERIVATIVES AS ANTIBACTERIALS SMITHKLINE BEECHAM PLC (GB) 2002-03-20 EP disclosed
WO-2000078748-A1 QUINOLINE DERIVATIVES AS ANTIBACTERIALS SMITHKLINE BEECHAM P.L.C. (GB) 2000-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203917-A1 Compounds and methods for the treatment of neoplastic disease TOP1, TOP2A, TOP2B PDK1 997/4885PDK2 1100/4885PDK3 1418/4885
US-10815222-B2 Compounds for use in the treatment of kinetoplastid infection NISCH, TK2, FDPS PDK1 42/4885PDK2 75/4885PDK3 123/4885
US-20200095232-A1 COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION NISCH, TK2, FDPS PDK1 42/4885PDK2 75/4885PDK3 123/4885
US-20250368625-A1 PIPERAZINES SSTR4, SSTR5, SSTR2 PDK1 2761/4885PDK2 1452/4885PDK3 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.